LFA
BIO icon

LGT Financial Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

LGT Financial Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-105
Closed -$34.5K – 348
2024
Q4 		$34.5K Hold
105
– – 0.08% 207
2024
Q3 		$35.1K Sell
105
-87
-45% -$27.6K 0.09% 177
2024
Q2 		$52.4K Sell
192
-80
-29% -$23.3K 0.11% 159
2024
Q1 		$94.1K Sell
272
-11
-4% -$3.62K 0.11% 181
2023
Q4 		$91.4K Buy
283
+11
+4% +$3.45K 0.11% 169
2023
Q3 		$97.5K Buy
+272
New +$105K 0.12% 158

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LGT Financial Advisors's BIO Position: Q1 2025 in Review

LGT Financial Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 105 shares — an estimated $34.5K sold.

LGT Financial Advisors first reported a position in BIO in Q3 2023 and held it in 6 quarters. The position peaked at $97.5K in Q3 2023. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • LGT Financial Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 105 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $34.5K.
  • LGT Financial Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Bio-Rad Laboratories Class A position peaked at $97.5K in Q3 2023.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.